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CLINICAL RESEARCH
HIV antigen and antibody detection: variable responses to
infection in the Edinburgh haemophiliac cohort
P SIMMONDS, F A L LAINSON, R CUTHBERT, C M STEEL, J F PEUTHERER,
C A LUDLAM
Abstract
Sequential serum samples from 18 haemophiliac patients
exposed simultaneously to human immunodeficiency virus type 1
(HIV 1) in early 1984 were tested retrospectively for sero-
logical markers of infection. Assay for total antibodies to HIV
established that the time to seroconversion might be as long as
110 days after exposure to contaminated factor VIII; serum
samples were also tested by Western blotting, by enzyme linked
immunosorbent assay (ELISA) for specific antibodies to
envelope and core proteins, and for p24 antigen by two assay
systems during the two years after infection. The studies showed
that five of the 12 patients for whom serum samples obtained
between exposure and seroconversion were available had
transient p24 antigenaemia. Although amounts of total antibody
to HIV and of antibodies to envelope proteins rose continuously
during the two years of the study, amounts of antibody to the
core protein were variable and tended to decline in patients
who became symptomatic. Two patients had persistent p24
antigenaemia that began four months after seroconversion; these
patients remained asymptomatic. One patient who developed the
acquired immune deficiency syndrome (AIDS) had transient
antigenaemia at the time ofseroconversion but failed to show any
antigen for the rest of the study; progression to AIDS was
accompanied by an increase in antibodies to envelope proteins.
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Much of the variability in the course of infection with HIV
must represent the differences in the susceptibility ofthe patients
to infection.
Introduction
Patients with haemophilia A are one of the groups at risk from
infection with the human immunodeficiency virus type 1 (HIV 1)
because they are treated with factor VIII concentrates. Infection
with the virus is associated with the appearance of specific antibody
that persists throughout the disease.' Detection of the antibody is
the current method of determining past exposure to the virus and is
used for screening blood donors and subjects at risk of infection.
Antibody can be detected by several methods, including enzyme
linked immunosorbent assays (ELISAs), radioimmunoprecipita-
tion, and Western blotting assays with purified virus as the antigen.
These tests differ in sensitivity and specificity.23 Antibodies are
directed against all the structural proteins encoded by the gag
(group specific or core), pol (polymerase), and env (envelope) genes
as well as the non-structural proteins.4 There is a prolonged stage of
infection with HIV 1, often lasting for several years, during which
the patient is free of symptoms. It is not known what proportion of
patients will eventually develop the full acquired immune deficiency
syndrome (AIDS); laboratory tests that could predict the time
course of progression in each patient would be of great clinical
value.
Free HIV protein, particularly p24, a core protein, is often
detected in serum samples from patients at certain stages of
infection. There is evidence that transient antigenaemia occurs
immediately before seroconversion.5 A decrease in reactivity
with HIV core proteins measured by Western blotting and a
commercially available test for antibody against the core protein in
serum samples from patients who have progressed to develop AIDS
has been observed.&" Immune complexes9 and free viral antigen'0
have been detected in patients with AIDS after the loss of reactivity
to p24. These findings suggest that there is a balance between the
rate of viral replication and the ability of the immune system to clear
the released virus.
In a previous report infection with HIV was described in a cohort
of haemophiliac patients from south east Scotand who had been
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maintained solely on locally produced factor VIII." In most
serological studies, including those in haemophiliac patients, the
precise time of exposure is unknown. In this study, however,
infection was acquired from a single batch of factor VIII during
a short period starting in March 1984. Furthermore, the low
prevalence of HIV 1 infection in Scotland in 1983, when blood for
the batch was collected, makes it probable that the batch was
contaminated by a single donation. The whole cohort may therefore
have been exposed to a single strain of HIV 1. This fact may
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antibody. Clinical state was determined in early 1987 and the patients
divided into "well" and "unwell" groups.
Western blotting-Purified HIV 1 viral lysate (Dupont) (20 ,ug) was
applied to the top of a band of polyacrylamide gel (12-5% acrylamide, 0-6%
NN-methylene-bis-acrylamide) 17 cm wide and electrophoresis carried out
by the discontinuous buffer system of Laemmli.'2 After overnight blotting
the nitrocellulose sheet was blocked in 1% bovine serum albumin and 1%
gelatin for 20 minutes at room temperature. Test or control serum was
diluted 1/50 in phosphate buffered saline with 0-2% Tween 20 and incubated
with a 2 mm strip of nitrocellulose for two hours at room temperature. The
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FIG 1-Relation between transfusion of factor VIII contaminated with HIV and detection of p24 antigen and
antibody specific for HIV. Boxes indicate length of time for which infected batch was administered; figure in box is
total number of units transfused.
become important should important variations in pathogenicity or
antigenicity be discovered between different isolates of HIV.
Infection in the cohort was investigated by retrospective testing of
stored serum samples from the patients. Antibody specific for HIV
was measured by Western blotting and by an ELISA using whole
virus, envelope protein, or core protein as antigen. Concentrations
of antigen in serum were measured by two commercially available
ELISAs. The data were compared with the clinical state of the
patients to determine whether progression to AIDS or AIDS related
complex correlated with any of the serological measurements.
Patients and methods
Thirty two haemophiliac patients were inadvertently transfused with a
contaminated batch of factor VIII from the Scottish National Blood
Transfusion Service in March 1984. There was no evidence of exposure to
HIV 1 before or after this in any ofthe patients. Eighteen patients underwent
seroconversion after transfusion, and these form the study group. One
patient (case 2) underwent seroconversion after leaving Edinburgh, and
although some clinical information about him was available serum samples
could not be tested and he was omitted from the study. Serum samples were
taken from the other patients for unrelated reasons at varying intervals from
before transfusion to the time of writing; samples were stored at -20°C and
tested retrospectively (up to 30 months' follow up). The concentrations of
p24 antigen were measured before seroconversion and at four monthly
intervals thereafter for the duration of the study. Amounts of antibody
against HIV were measured in all positive samples, and amounts ofantibody
against envelope protein were measured immediately after seroconversion,
after one year, and after two years. Antibodies against core protein were
measured in the same samples, and more often in any patients whose amount
of antibody fell during any part of the study. No samples were available for
three patients after the first year of infection, and so they could not be
included in the comparison of clinical progression and amounts of core
second antibody was horseradish peroxidase conjugated antihuman IgG
(Scottish Antibody Production Unit) diluted 1/200 in phosphate buffered
saline with Tween 20 and incubated in the same way as the first antibody.
The substrate was diaminobenzidine in phosphate buffered saline, pH 7-6.
Measurement of total antibody (anti-HIV)-A direct binding assay
(Dupont) was used to compare amounts of antibody. The test is a two step
indirect ELISA comprising a first incubation of a 1/11 dilution of test serum
in an antigen coated well and a second incubation with an alkaline
phosphatase conjugated antihuman IgG conjugate, and a colour reaction test
with paranitrophenol. Three serum samples with antibody to HIV 1 were
diluted serially in serum samples that had yielded negative results when
tested in this assay. There was an exact linear relation between the amount of
antibody and optical density in the range 0-0-8. Unknown samples were
tested at two dilutions (generally 1/100 and 1/1000, final test dilutions 1/1100
and 1/11 000) in the assay that included multiple replicates of the control
serum that had yielded a positive titre diluted at 1/1000. Simple division of
the test optical density (providing that the value lay in the range 0-0 8) by the
control positive optical density gave an amount of antibody relative to
the positive control. Results were expressed in units (U), with the positive
control arbitrarily assigned 1000 U.
Antibody against core and envelope proteins-The Abbott confirmation
(envelope/core) assay is a competition assay between antibody to HIV
labelled with horseradish peroxidase and test serum at a 1/5 dilution for
cloned deoxyribonucleic acid (DNA) core protein (mainly p24) and cloned
DNA envelope protein (mainly unglycosylated gp4l). Serial dilutions of
positive samples were made in samples that had yielded negative results and
tested in the Abbott envelope/core confirmation assay. Optical density
readings of test samples (at two appropriate dilutions) were related
graphically to a standard dilution curve of the amount of antibody in the
positive control serum. The difference in antibody dilution was used to
calculate a relative antibody level provided that the optical density values
were in the range 0-15-0-80. Results were expressed in units (as defined
above).
Antigen (p24) detection-The antigen capture ELISA (Dupont) was used
for most of the study. Results were expressed in pg/ml calculated from a
standard curve. Samples yielding positive results were also tested by the
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FIG 2-Antibody to HIV and to envelope protein in well and unwell patients.
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Abbott ELISA with good reproducibility and comparable sensitivity. The
presence of antigen in samples from two patients in whom it had reappeared
after seroconversion was confirmed by neutralisation with neutralising and
control antisera from Abbott, and independently by human control samples
that were positive and negative for antibody to HIV.
Results
CLINICAL COURSE OF INFECTION
Although the 18 patients in the study were infected at about the same time
with the same material, they differed in their current clinical state of HIV
infection. Ten patients (cases 1-10) remained asymptomatic. Table I
gives details of the remaining eight patients, who developed symptoms
before March 1987 (cases 11-18). Two of the patients classified as well also
developed splenomegaly; although this may be the result of HIV infection,
splenomegaly may occur in haemophiliac patients for other reasons. There
was no other evidence of progression of disease in these two patients, and so
they were classified as well. The unwell group (eight patients) comprised
those with AIDS, AIDS related complex, and persistent generalised
lymphadenopathy.
TABLE I-Clinical state ofunwell patients
Case No Development of symptoms
11 Normal at 12 months; persistent generalised lymphadenopathy at 17 months
12 Disease similar to glandular fever at seroconversion; AIDS related complex at nine
months, AIDS at 13 months
13 AIDS related complex at 28 months
14 AIDS related complex at 29months
15 Persistent generalised lymphadenopathy at 11 months
16 AIDS related complex at 31 months (onset probably 25-26 months)
17 Normal at six months; persistent generalised lymphadenopathy at 12 months
18 AIDS related complex at 22 months
SEROCONVERSION
Figure 1 shows the time taken for HIV antigen and antibody to appear
after transfusion of the contaminated factor VIII. Antigen was detected in
serum samples from five patients before or at the time of seroconversion.
The actual prevalence ofantigenaemia may have been higher as, because it is
a transient phenomenon, its detection depends on having a sample taken at
the appropriate time. The antigenaemia seemed to last a fairly short time, the
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longest periods being 35 days in case 12 and 70 days in case 8. The antigen
concentration varied between patients, ranging from 20 pg/ml (case 6) to
3600 pg/ml (case 18). This latter figure was the highest observed and may
have been related to the transfusion of a large amount of factor VIII
(109 units) over only 35 days.
Serum samples were tested by Western blotting and for antibody against
envelope protein by ELISA for the earliest signs of seroconversion. The two
tests were in complete agreement about which samples did and did not show
antibody. There was no evidence that antibody against envelope protein was
detectable before the appearance of antibody reactivity by Western blotting
in any of the patients. Western blotting was less sensitive for antibody to
gp4l than the specific ELISA, as nine of the first positive samples reacted
only with core proteins (p24 and prS5) in the Western blotting assay.
Reactivity with gp4l in the Western blotting assay appeared some weeks
differences in units of antibodies among the patients with persistent
generalised lymphadenopathy, AIDS related complex, or AIDS.
Antibody to core protein was also measured by ELISA, but the same sort
of upward trend was not observed in all patients. Eight patients, seven well
and one with persistent generalised lymphadenopathy (case 15), showed
steadily rising numbers of units of antibody to core protein over the two year
follow up period, although there was considerable variation in the values
finally achieved. Serum samples from all eight patients were negative for
p24 antigen throughout.
Four patients showed falls in the number of units of antibody to core
protein within months of seroconversion (table II). To confirm this
observation the same serum samples were tested by Western blotting; those
from case 12 are shown in figure 3. There was good correlation between the
observed intensity of the p24 band and the number of units of anticore
TABLE iI-Patients in whom anticore antibody levelsfell duringfollow up period
Case No Diagnosis
12* AIDS Days after transfusion 36 101 123 243 416 607 808 1048Titres (units) 2-7 8-4 5-7 2-8 1 1 1-2 0 0
13* AIDSrelatedcomplex Daysaftertransfusion 27 117 180 330 80713* AIDSrelatedcom 1 ~Titres (units) 0 2-7 4-7 0 0
17* Persistent generalised lymphadenopathy I Daysafter transfusion 83 212 381 728 916Titres (units) 1-7 75 15 15 0
Days after transfusion 77 271 475 629
1 Well Titres (units) 1-6 0 0 0
Antigen (pg/ml) 0 20 18
*Serum samples yielded negative results to p24 antigen.
TABLE III-Patients in whom anticore antibody levels rose afterfalling orfluctuated duringfollow up period
Case No Diagnosis
14* AIDSrelatedf Daysaftertransfusion 85 107 210 231 416 540 694 83314* AIDS elatedcomplex l Titres(units) 1-7 19 0 5 0 1 1 2-6 4-8 18
1* AIDS related complex Days after transfusion 14 198 258 327 433 88716* AIDS related complex { Titres (units) 0 1 1 4 11 4 9
Days after transfusion 150 245 332 598 844
8 Well Titres(units) 1-4 1-7 0 5 7-9 8-9
Antigen (pg/ml) 0 35 20 80 200
*Serum samples were negative for p24 antigen.
later in these patients. The appearance of anticore protein reactivity was
delayed when measured by the specific ELISA in two patients (cases 5 and
11). Their serum samples were, however, positive for p24 antibody by
Western blotting, reflecting the difference in sensitivity of the two tests.
Absence of anticore protein reactivity in the presence of serum antigen was
observed in case 11 at 196 days, although one patient (case 12) showed serum
antigen and anticore protein reactivity at the same time (35 days). One
patient (case 10) was unusual in that the first positive and all subsequent
serum samples during the two year follow up failed to react with core
protein and to p24 in the Western blotting assay and were negative for
p24 antigen.
The time to seroconversion after transfusion varied among individual
patients. One patient (case 1 1) developed antibody at least 160 days after first
transfusion, though antibody appeared in serum from case 12 between days
30 and 36. There seemed to be some association between the amount of
factor VIII transfused and the time to seroconversion, but the varied times of
sampling for each patient made this difficult to prove.
FOLLOW UP PERIOD
Figure 2 shows units of total antibody specific for HIV and antibody
against envelope protein in all patients over the two year follow up period.
There were consistent upward trends in both the well and unwell patients,
with large individual variations. There was no statistical difference,
however, in the average units of antibody to HIV between the well and
unwell groups at one year or at two years after transfusion. Similarly, there
was no significant difference in antibodies against envelope protein between
the two groups. Within the unwell group there were no consistent
protein antibody in all four patients, although samples negative for the
antibody as measured by ELISA often showed a weak p24 band by blot.
In case 1 small amounts of p24 antigen were detected 271 days after
exposure and persisted for the remainder of the follow up period. One
patient (case 13) may have had small amounts of antigen on more than one
occasion after seroconversion, but samples were not always reactive and
were negative by the Abbott antigen test. All samples from the other two
patients were negative for antigen.
Two patients showed a different pattern (table III, fig 4); one (case 14)
showed rising amounts of antibody to core protein after seroconversion and
then a fall, becoming negative by the ELISA and unreactive with p24 by
Western blotting. Antibody reappeared, however, some months later, and
the amount continued to rise for the rest of the study period. A similar
pattern was observed in case 8. A rising concentration of p24 antigen was
detected in this patient from day 245 onward, despite the reappearance of
antibody to core protein. One patient (case 16) (table III) was harder to
categorise as he showed fluctuating amounts of anticore protein antibody
after seroconversion and weak p24 blot reactivity, and was consistently
negative for p24 antigen.
Discussion
Testing serum samples after transfusion of the implicated batch
of factor VIII allowed an estimate of the incubation period before
seroconversion. This turned out to be variable, ranging from less
than 35 days in one patient to over 160 days in another. There was
some evidence that seroconversions occurred more rapidly in
596
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patients who were given larger amounts of the implicated batch of
factor VIII. This would emphasise the association found previously
between the larger amount of the contaminated batch used by
these 18 patients compared with the 14 patients who remained
seronegative."I
There was a transient antigenaemia, which was variable in both
degree and duration, in at least five patients before seroconversion,
similar to that reported by Allain et al.6 A particularly high
FIG 3-Reactivity ofsequential serum samples from case 12 in Western blot assay.
concentration (3600 pg/ml) was found in one patient who had been
given a lot of factor VIII over a fairly short period. The delayed
appearance of antibody to core protein by specific ELISA on
seroconversion noted by Allain et al6 was found in this study, but the
serum samples were reactive with p24 on Western blotting,
indicating the low sensitivity of the ELISA for the antibody. By
contrast, the ELISA for the antienvelope protein antibody was more
sensitive for glycoprotein antibody than the Western blotting assay.
All patients showed rises in amounts of antibody to HIV and to
envelope protein during the follow up period. Five patients
developed AIDS related complex and AIDS despite rising titres of
597
antienvelope protein antibody, indicating that this antibody is not
protective once patients are infected. The rise in titres may indicate
continual stimulation of the immune system by viral replication;
if this is the case the similar amounts of antibody in the well and
unwell groups indicate a poor prognosis for patients even if they
remain asymptomatic.
Although antigen could readily be detected before seroconversion,
only two patients (both well) showed long term antigenaemia. This
is a low prevalence compared with the results of other investigators
and may reflect the short time that the patients had been infected.'0
It is notable, however, that the patient who developed AIDS
remained negative for p24 antigen after seroconversion despite
ar.5 W.,. 10. .....
i'107 231 33 4t 54 894t ?1d;-
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FIG 4-Reactivity of sequential serum samples from case 14 in Western blot assay.
frequent testing. Similarly, serum samples from at least three of the
four patients with AIDS related complex yielded consistently
negative results over the study period.
Levels of antibody to core protein were the most variable
measurement, both among individuals and with time, and they
correlated to a certain extent with clinical outcome. Patients with
steadily rising antibody titres were well, except for one with
persistent generalised lymphadenopathy. Conversely, all patients
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with AIDS or AIDS related complex showed abnormal losses of the
antibody. There were, however, two well patients and one with
persistent generalised lymphadenopathy who also showed loss of
antibody to core protein. It is certainly possible that these patients
may subsequently develop symptoms, but none had any clinical
evidence of immunosuppression at the time of writing. The
importance ofthe reappearance ofantibody to core protein observed
in two patients is not clear; one had AIDS related complex, so it does
not seem to reflect recovery from infection.
This small cohort ofhaemophiliac patients allowed us to study the
antigen and antibody responses to HIV infection acquired at a
known time from a single source. Although the infectious dose
administered to each patient was different, much of the variability
in the course of infection was clearly the result of differences in
susceptibility of the patients to infection. Human leucocyte antigen
and other population markers have been investigated as possible
related factors (unpublished observations).
PS was funded by the faculty of medicine, University of Edinburgh. The
study was supported by the Medical Research Council and Scottish Home
and Health Department. We thank the staff of the hepatitis and AIDS
reference laboratory, Edinburgh, for making available stored serum samples
from the haemophiliac patients.
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Early growth delay in diabetic pregnancy: relation to psychomotor
development at age 4
MINNA BLOCH PETERSEN, S0REN ANKER PEDERSEN, GORM GREISEN,
JAN FOG PEDERSEN, LARS M0LSTED-PEDERSEN
Abstract
Ninety nine consecutive insulin dependent and 101 non-diabetic
pregnant women were examined by ultrasonograph to assess
early fetal growth. In 42 of the diabetic mothers and three of the
non-diabetic mothers the scan showed early intrauterine growth
delay. At 4-5 years of age ali children available for study were
evaluated by the Denver developmental screening test. Only 23
of the 34 children of diabetic mothers with early intrauterine
growth delay had normal test scores compared with 46 of the 50
children of diabetic mothers with normal intrauterine growth.
The children failed in personal-social development, gross motor
development, and particularly in language and speech develop-
ment. Children of diabetic mothers with normal early fetal
growth had scores very similar to those of the children of non-
diabetic mothers, ofwhom 76 ofthe 86 tested had normal scores.
Rigshospitalet, State University Hospital, Blegdamsvej 9, DK-2100
Copenhagen 0, Denmark
MINNA BLOCH PETERSEN, MD, senior registrar, department ofneonatology
S0REN ANKER PEDERSEN, MD, senior registrar, department ofneonatology
GORM GREISEN, MD, research associate, department of neonatology
LARS M0LSTED-PEDERSEN, MD, PHD, senior lecturer in obstetrics and
gynaecology
Glostrup Hospital, University of Copenhagen, Denmark
JAN FOG PEDERSEN, MD, PHD, chief of ultrasound laboratory
Correspondence to: Dr Bloch Petersen.
This study suggests that children with a history ofgrowth delay
in early diabetic pregnancy should be screened for possible
developmental impairment.
Introduction
We have shown that growth of the embryo in very early diabetic
pregnancy may be impaired, so that ultrasound scanning at eight to
14 weeks shows a smaller fetus than expected from the menstrual
history. Such growth retarded fetuses have an increased risk of
malformations.2 There is clinical evidence that impaired metabolic
compensation at conception and in early pregnancy may be related
to early intrauterine growth delay' 3 as well as to malformations.4
This paper reports the results of the Denver developmental
screening test56 in children aged 4 years with a history of fetal
growth delay in early diabetic pregnancy. The study tested the
hypothesis that these children would show developmental delay.
Patients and methods
During October 1976 to February 1980 ultrasound scanning (JFP) with
measurement of fetal crown-rump length was performed in 99 insulin
dependent diabetic mothers (about half of all diabetic pregnancies) and 101
non-diabetic mothers (2-4% of non-diabetic pregnancies). Details of these
studies have been reported.27 Three fetuses of the non-diabetic mothers and
42 of the diabetic mothers were smaller than normal in early pregnancy-
that is, retrospectively defined as a female fetus being seven or more days and
a male fetus five or more days smaller than expected from the menstrual
history.8 In the diabetic women delivery was induced 18 to 20 days before
term. All infants of the diabetic mothers and some infants ofthe non-diabetic
mothers were admitted to the neonatal intensive care unit.
